Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.

Sponsor
October 6 University
Study ID
NCT04779047
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 88 Years
Healthy Volunteers
Not accepted

Interventions

  • Remdesivir — DRUG
    Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.
  • Hydroxychloroquine — DRUG
    Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.
  • Tocilizumab — DRUG
    Tocilizumab 800 mg once.
  • Lopinavir/ Ritonavir — DRUG
    Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
  • Ivermectin — DRUG
    Ivermectin 36 mg at day 1,3 and 6.

Study Details

Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received different Antiviral and Anti Inflammatory Drugs.

Key Dates

Start date
Oct 1, 2020
Status verified
Mar 2021
Primary completion
Mar 10, 2021
Completion
Apr 5, 2021

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: group 1
    Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days plus tocilizumab 800 mg once
  • Active Comparator: group 2
    Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days and Ivermectin 36 mg at day 1,3 and 6 plus tocilizumab 800 mg once.

Primary Outcome Measure

Percentage of clinical cure in each arm [ Time Frame: through an average of 5-7 days ]

Central Contacts

Related Studies